MedTrace Logo

A Study to Evaluate the Efficacy and Safety of AD-208

NCT04825561 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 139

Last updated 2023-07-21

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of AD-208.

Conditions

Interventions

DRUG

AD-208

PO, Once daily(QD), 24weeks

DRUG

AD-2081

PO, Once daily(QD), 24weeks

DRUG

placebo of AD-208

PO, Once daily(QD), 24weeks

DRUG

placebo of AD-2081

PO, Once daily(QD), 24weeks

Sponsors & Collaborators

  • Addpharma Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-09
Primary Completion
2023-01-09
Completion
2023-06-01

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04825561 on ClinicalTrials.gov